All In Biotech

NDA 207947 · Actelion

Uptravi

Selexipag · Oral · Prostacyclin Receptor Agonist

NovelOrphan

Last checked: Nov 20, 2026Latest source record: May 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Dec 21, 2015

Approved uses

3

Original approval plus efficacy supplements

Registered trials

28

9 Phase 3, 3 recruiting

FAERS reports

26,100

19,535 serious, 4,907 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 28, 2026.

UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I): In adults to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) In pediatric patients aged 2 years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Adult Patients UPTRAVI is indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of UPTRAVI tablets was established in a long-term study in adult PAH patients with WHO Functional Class II–III symptoms. Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%) [see Clinical Studies (14.1) ] . Pediatric Patients UPTRAVI is indicated for the treatment of PAH (WHO Group I) in pediatric patients aged two years and older. UPTRAVI reduces NT-proBNP and is expected to delay disease progression and reduce the risk of hospitalization for PAH.

Mechanism: Selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin. Selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag. Selexipag and the active metabolite are selective for the IP receptor versus other prostanoid receptors (EP 1–4 , DP, FP, and TP).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

10 products under this application
  • UPTRAVI · SELEXIPAG 0.2MG · TABLET, ORAL · Prescription · TE AB
  • UPTRAVI · SELEXIPAG 1.6MG · TABLET, ORAL · Prescription · TE AB
  • UPTRAVI · SELEXIPAG 1.2MG · TABLET, ORAL · Prescription · TE AB
  • UPTRAVI · SELEXIPAG 0.8MG · TABLET, ORAL · Prescription · TE AB
  • UPTRAVI · SELEXIPAG 0.1MG · TABLET, ORAL · Prescription
  • UPTRAVI · SELEXIPAG 0.4MG · TABLET, ORAL · Prescription · TE AB
  • UPTRAVI · SELEXIPAG 1.4MG · TABLET, ORAL · Prescription · TE AB
  • UPTRAVI · SELEXIPAG 1MG · TABLET, ORAL · Prescription · TE AB
  • UPTRAVI · SELEXIPAG 0.15MG · TABLET, ORAL · Prescription
  • UPTRAVI · SELEXIPAG 0.6MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Selexipag" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache6,834
  • diarrhoea5,244
  • dyspnoea4,841
  • nausea4,153
  • fatigue2,651
  • death2,559
  • pain in jaw2,455
  • dizziness2,338
  • pain2,250
  • pain in extremity2,149
  • myalgia2,008
  • vomiting1,970

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20122
20132
20145
201526
20161,557
20172,388
20183,027
20193,219
20203,248
20212,807
20222,261
20232,301
20242,240
20251,807
20261,210

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Uptravi* (Selexipag)

2024 spending

$909M

Beneficiaries

4,320

39,389 claims

Per beneficiary

$210,364

$354.19 per unit

View as table
YearSpending
2020$540,954,176
2021$614,909,881
2022$582,841,269
2023$758,070,464
2024$908,772,074

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 58 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.